Short-duration therapy with daclatasvir/asunaprevir/beclabuvir fixed-dose combination plus sofosbuvir in patients with chronic hepatitis C genotype 1 (FOURward Study)

被引：0
|
作者：
Sulkowski, Mark S. [1 ]
Flamm, Steven L. [2 ]
Kayali, Zeid [3 ]
Lawitz, Eric [4 ]
Kwo, Paul Y. [5 ]
McPhee, Fiona [6 ]
Torbeyns, Anne [7 ]
Hughes, Eric A. [8 ]
Swenson, Eugene S. [6 ]
Yin, Philip [6 ]
Linaberry, Misti [8 ]
机构：
[1] Johns Hopkins Univ, Baltimore, MD USA
[2] Northwestern Univ, Chicago, IL 60611 USA
[3] Inland Empire Liver Fdn, Rialto, CA USA
[4] Univ Texas Hlth Sci Ctr San Antonio, Texas Liver Inst, San Antonio, TX 78229 USA
[5] Indiana Univ, Indianapolis, IN 46204 USA
[6] Bristol Myers Squibb Co, Wallingford, CT 06492 USA
[7] Bristol Myers Squibb, Braine Lalleud, Belgium
[8] Bristol Myers Squibb Co, Princeton, NJ USA
来源：
HEPATOLOGY | 2015年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
702
引用
收藏
页码：556A / 556A
页数：1
相关论文
共 50 条
  • [31] Hemoglobin Decrease with Iron Deficiency Induced by Daclatasvir plus Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b
    Matsumoto, Nobuyuki
    Ikeda, Hiroki
    Shigefuku, Ryuta
    Hattori, Nobuhiro
    Watanabe, Tsunamasa
    Matsunaga, Kotaro
    Hiraishi, Tetsuya
    Tamura, Tomohiro
    Noguchi, Yohei
    Fukuda, Yasunobu
    Ishii, Toshiya
    Okuse, Chiaki
    Sato, Akira
    Suzuki, Michihiro
    Itoh, Fumio
    PLOS ONE, 2016, 11 (03):
  • [32] Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C
    Goki Suda
    Mineo Kudo
    Atsushi Nagasaka
    Ken Furuya
    Yoshiya Yamamoto
    Tomoe Kobayashi
    Keisuke Shinada
    Miki Tateyama
    Jun Konno
    Yoko Tsukuda
    Kazushi Yamasaki
    Megumi Kimura
    Machiko Umemura
    Takaaki Izumi
    Seiji Tsunematsu
    Fumiyuki Sato
    Katsumi Terashita
    Masato Nakai
    Hiromasa Horimoto
    Takuya Sho
    Mitsuteru Natsuizaka
    Kenichi Morikawa
    Koji Ogawa
    Naoya Sakamoto
    Journal of Gastroenterology, 2016, 51 : 733 - 740
  • [33] LEDIPASVIR/SOFOSBUVIR FIXED-DOSE COMBINATION FOR TREATMENT OF HEPATITIS C VIRUS GENOTYPE 4 INFECTION
    Nehra, V.
    Tan, E. M.
    Rizza, S. A.
    Temesgen, Z.
    DRUGS OF TODAY, 2016, 52 (02) : 111 - 117
  • [34] Real-world virological efficacy and safety of daclatasvir/asunaprevir/beclabuvir in patients with chronic hepatitis C virus genotype 1 infection in Japan
    Takaguchi, Koichi
    Toyoda, Hidenori
    Tsutsui, Akemi
    Suzuki, Yoshiyuki
    Nakamuta, Makoto
    Imamura, Michio
    Senoh, Tomonori
    Nagano, Takuya
    Tada, Toshifumi
    Tachi, Yoshihiko
    Hiraoka, Atsushi
    Michitaka, Kojiro
    Shibata, Hiroshi
    Joko, Kouji
    Okubo, Hironao
    Tsuji, Kunihiko
    Takaki, Shintaro
    Watanabe, Tsunamasa
    Ogawa, Chikara
    Chayama, Kazuaki
    Kumada, Takashi
    Kudo, Masatoshi
    Kumada, Hiromitsu
    JOURNAL OF GASTROENTEROLOGY, 2019, 54 (08) : 742 - 751
  • [35] Potent viral suppression and improvements in alpha-fetoprotein and measures of fibrosis in Japanese patients receiving a daclatasvir/asunaprevir/beclabuvir fixed-dose combination for the treatment of HCV genotype-1 infection
    Akuta, Norio
    Toyota, Joji
    Karino, Yoshiyasu
    Ikeda, Fusao
    Ido, Akio
    Tanaka, Katsuaki
    Takaguchi, Koichi
    Naganuma, Atsushi
    Tomita, Eiichi
    Chayama, Kazuaki
    Fujiyama, Shigetoshi
    Inada, Yukiko
    Yoshiji, Hitoshi
    Watanabe, Hideaki
    Ishikawa, Hiroki
    McPhee, Fiona
    Noviello, Stephanie
    Kumada, Hiromitsu
    JOURNAL OF GASTROENTEROLOGY, 2018, 53 (09) : 1089 - 1097
  • [36] Sofosbuvir/velpatasvir fixed-dose combination for the treatment of chronic hepatitis C virus infection
    Nehra, V.
    Rizza, S. A.
    Temesgen, Z.
    DRUGS OF TODAY, 2017, 53 (03) : 177 - 189
  • [37] Potent viral suppression and improvements in alpha-fetoprotein and measures of fibrosis in Japanese patients receiving a daclatasvir/asunaprevir/beclabuvir fixed-dose combination for the treatment of HCV genotype-1 infection
    Norio Akuta
    Joji Toyota
    Yoshiyasu Karino
    Fusao Ikeda
    Akio Ido
    Katsuaki Tanaka
    Koichi Takaguchi
    Atsushi Naganuma
    Eiichi Tomita
    Kazuaki Chayama
    Shigetoshi Fujiyama
    Yukiko Inada
    Hitoshi Yoshiji
    Hideaki Watanabe
    Hiroki Ishikawa
    Fiona McPhee
    Stephanie Noviello
    Hiromitsu Kumada
    Journal of Gastroenterology, 2018, 53 : 1089 - 1097
  • [38] Safety and efficacy of once daily ledipasvir/sofosbuvir fixed-dose combination in patients with chronic hepatitis C
    Gamal, N.
    Andreone, P.
    EXPERT OPINION ON DRUG SAFETY, 2016, 15 (04) : 549 - 557
  • [39] Efficacy and Safety of Daclatasvir Plus Asunaprevir Therapy for Chronic Hepatitis C Patients With Renal Dysfunction
    Nakamura, Yuki
    Imamura, Michio
    Kawakami, Yoshiiku
    Teraoka, Yuji
    Daijo, Kana
    Honda, Fumi
    Morio, Kei
    Kobayashi, Tomoki
    Nakahara, Takashi
    Nagaoki, Yuko
    Kawaoka, Tomokazu
    Tsuge, Masataka
    Hiramatsu, Akira
    Aikata, Hiroshi
    Hayes, C. Nelson
    Miki, Daiki
    Ochi, Hidenori
    Chayama, Kazuaki
    JOURNAL OF MEDICAL VIROLOGY, 2017, 89 (04) : 665 - 671
  • [40] A prospective, multicenter study of daclatasvir and asunaprevir combination therapy for chronic hepatitis C virus genotype 1b infection on hemodialysis
    Sung, Jihyun
    Uojima, Haruki
    Ohtake, Takayasu
    Kinbara, Takeshi
    Oka, Machiko
    Matsumoto, Shuichi
    Kobayashi, Shuzo
    Kako, Makoto
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 : 354 - 355
12345